These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 21988996)
21. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476 [TBL] [Abstract][Full Text] [Related]
22. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. Hessell AJ; Rakasz EG; Poignard P; Hangartner L; Landucci G; Forthal DN; Koff WC; Watkins DI; Burton DR PLoS Pathog; 2009 May; 5(5):e1000433. PubMed ID: 19436712 [TBL] [Abstract][Full Text] [Related]
23. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. Gautam R; Nishimura Y; Lee WR; Donau O; Buckler-White A; Shingai M; Sadjadpour R; Schmidt SD; LaBranche CC; Keele BF; Montefiori D; Mascola JR; Martin MA J Virol; 2012 Aug; 86(16):8516-26. PubMed ID: 22647691 [TBL] [Abstract][Full Text] [Related]
24. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. Bertley FM; Kozlowski PA; Wang SW; Chappelle J; Patel J; Sonuyi O; Mazzara G; Montefiori D; Carville A; Mansfield KG; Aldovini A J Immunol; 2004 Mar; 172(6):3745-57. PubMed ID: 15004179 [TBL] [Abstract][Full Text] [Related]
25. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Barouch DH; Santra S; Schmitz JE; Kuroda MJ; Fu TM; Wagner W; Bilska M; Craiu A; Zheng XX; Krivulka GR; Beaudry K; Lifton MA; Nickerson CE; Trigona WL; Punt K; Freed DC; Guan L; Dubey S; Casimiro D; Simon A; Davies ME; Chastain M; Strom TB; Gelman RS; Montefiori DC; Lewis MG; Emini EA; Shiver JW; Letvin NL Science; 2000 Oct; 290(5491):486-92. PubMed ID: 11039923 [TBL] [Abstract][Full Text] [Related]
27. Protection of SIVmac-infected macaque monkeys against superinfection by a simian immunodeficiency virus expressing envelope glycoproteins of HIV type 1. Dunn CS; Hurtrel B; Beyer C; Gloeckler L; Ledger TN; Moog C; Kieny MP; Mehtali M; Schmitt D; Gut JP; Kirn A; Aubertin AM AIDS Res Hum Retroviruses; 1997 Jul; 13(11):913-22. PubMed ID: 9223407 [TBL] [Abstract][Full Text] [Related]
28. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques. Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675 [TBL] [Abstract][Full Text] [Related]
29. Humoral immunity to HIV, SIV, and SHIV. Haigwood NL; Zolla-Pazner S AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993 [No Abstract] [Full Text] [Related]
30. Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine. Qureshi H; Ma ZM; Huang Y; Hodge G; Thomas MA; DiPasquale J; DeSilva V; Fritts L; Bett AJ; Casimiro DR; Shiver JW; Robert-Guroff M; Robertson MN; McChesney MB; Gilbert PB; Miller CJ J Virol; 2012 Feb; 86(4):2239-50. PubMed ID: 22156519 [TBL] [Abstract][Full Text] [Related]
32. Antibodies and resistance to natural HIV infection. Nabel GJ; Sullivan NJ N Engl J Med; 2000 Oct; 343(17):1263-5. PubMed ID: 11071680 [No Abstract] [Full Text] [Related]
33. Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque model. Page M; Stebbings R; Berry N; Hull R; Ferguson D; Davis L; Duffy L; Elsley W; Hall J; Ham C; Hassall M; Li B; Mee ET; Quartey-Papafio R; Rose NJ; Mathy N; Voss G; Stott EJ; Almond N Retrovirology; 2012 Jul; 9():56. PubMed ID: 22799593 [TBL] [Abstract][Full Text] [Related]
34. Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012. Girard MP; Picot V; Longuet C; Nabel GJ Vaccine; 2013 Jun; 31(29):2979-83. PubMed ID: 23499518 [TBL] [Abstract][Full Text] [Related]
36. Why do we not have an HIV vaccine and how can we make one? Burton DR; Moore JP Nat Med; 1998 May; 4(5 Suppl):495-8. PubMed ID: 9585194 [No Abstract] [Full Text] [Related]
38. Relevance of studying T cell responses in SIV-infected rhesus macaques. Valentine LE; Watkins DI Trends Microbiol; 2008 Dec; 16(12):605-11. PubMed ID: 18964016 [TBL] [Abstract][Full Text] [Related]
39. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Lifson JD; Haigwood NL Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a007310. PubMed ID: 22675663 [TBL] [Abstract][Full Text] [Related]
40. HIV vaccine development: lessons from the past and promise for the future. Spearman P Curr HIV Res; 2003 Jan; 1(1):101-20. PubMed ID: 15043215 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]